News | Atrial Fibrillation | October 21, 2024

HRS Creates New Advocacy Organization

The new advocacy organization will help address the needs of electrophysiologists and their patients.


Oct. 18, 2024 — The Heart Rhythm Society (HRS) Board of Trustees unanimously approved the formation of Heart Rhythm Advocates, a new, shared vision, cause-related nonprofit 501(c)(4) advocacy organization to complement the primary 501(c)(3) nonprofit structure of the HRS.

 This announcement comes at a time when atrial fibrillation (AF) is on the rise, affecting more than 10.5 million Americans.A growing patient population, increase in electrophysiology procedures, and rapid innovation in the field have led to elevated government scrutiny on cost, resulting in drastic cuts for reimbursement for common AF procedures. Reductions in reimbursement are making it difficult to retain and attract heart rhythm specialists. Without enough trained cardiac electrophysiologists (EPs), patients with heart rhythm disorders will be at a greater risk of limited access to quality care.

Under its previous structure, HRS led numerous efforts to protect fair reimbursement for AF ablation, gain approval for pulsed field ablation codes, and include ambulatory surgery centers for coverage. The establishment of  Heart Rhythm Advocates  allows for greater lobbying influence and political activity for the benefit of both patients and HRS members. With more than 45 years of experience advocating for the cardiac electrophysiology (EP) specialty, HRS will be providing $1,000,000 in initial funding to establish its new advocacy arm.

“Heart Rhythm Advocates offers a powerful way to further strengthen HRS’ leadership and commitment to serving as the unified voice of EP. This new entity will allow us to expand our impact and support everyone in the EP community, starting with physicians and their patients.” Said Kenneth A. Ellenbogen, MD, FHRS, Heart Rhythm Society President. “By taking this big step forward and with the continued support of our members and patients, we will accelerate Heart Rhythm Advocates' ability to influence reimbursement and healthcare policies for the current and future generations of EPs.”

Heart Rhythm Advocates will allow HRS to better address the needs of U.S. members and their patients without compromising the Society’s global mission of ending death and suffering due to heart rhythm disorders. By establishing a new entity solely focused on advocating for EPs and all the specialty’s stakeholders, HRS further strengthens the organization’s dual focus of advancing knowledge and driving innovation. HRS will continue to offer updates on the leading priorities for serving the EP specialty and how members can become involved with Heart Rhythm Advocates.

1. Noubiap JJ, Tang JJ, Teraoka JT, Dewland TA, Marcus GM. Minimum national prevalence of diagnosed atrial fibrillation inferred from California acute care facilities. Journal of the American College of Cardiology. 2024; 84(16): 1501-1508.


Related Content

News | Atrial Fibrillation

Sept. 11, 2024 — In the first national estimate in two decades, researchers at the University of California-San ...

Home September 11, 2024
Home
News | Atrial Fibrillation

July 24, 2024 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist ...

Home July 24, 2024
Home
News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
Subscribe Now